PLATINUM AND GOLD SPONSORS
SPONSORS
SPONSORS
SUPPORTED BY
Mark Fish is a Managing Director in Accenture, and Global Lead for Accenture Scientific Informatics Services. Mark has over 25 years of experience in leadership roles in Accenture, Azenta and Thermo Fisher Scientific delivering innovative research and development solutions to the pharmaceutical sector and other industries. Mark is passionate about drug discovery and development, with extensive experience in translation research and precision medicine, digital transformation, agile software development and robotic automation in analytical quality control, compound management and high throughput screening. Mark is an advocate for a managed scientist first approach to laboratory transformation that focusses on diagnostic and assessment to define value based outcomes and priorities to guide technology implementation and adoption.
As Vice President and General Manager for the Digital Science Solutions division at Thermo Fisher Scientific, Richard is responsible for driving revenue and customer engagement with our core digital science and informatics capabilities.
Richard Milne has more than 20 years of experience in the world of digital marketing, eBusiness, customer experience and developing web properties. Richard is passionate about the changing nature of business and has long believed the future will be digital—where automation, AI, data science, IoT, connected devices and eCommerce become the main ways customers interact with companies.
Prior to joining the company 15 years ago, he worked as an internet technologies consultant for the Scottish Government. And before that, he championed early digital marketing by building eCommerce websites and leading direct marketing campaigns for large CPG clients.
Richard is inspired by the changing landscape of commerce, the power of partnership and the ever-increasing value of platform thinking.
Rob Brown is VP of Product and PreSales at Sapio Sciences. Prior to joining Sapio Sciences he spent eight years at Dotmatics where he held various positions including Head of Global Presales and Head of Product Marketing & Product Management. Earlier in his career he was responsible for product marketing teams for cheminformatics and bioinformatics at Accelrys, SciTegic and MSI. Rob started his career as a postdoc and later research scientist in the Computer Aided Molecular Design department at Abbott Laboratories (now Abbvie). He received his PhD in Cheminformatics from the University of Sheffield, UK.
Kristina started her career as a Cell and Molecular Biologist at Eurofins Lancaster Labs and joined GSK in 2018 as a Biopharm process development scientist, working at the interface of late-stage development and commercial manufacturing . In 2021, she joined the Digital and Data Analytics program within GSK, focused on building digital infrastructure that enables scientists to capture experiments with ease while focusing on the critical scientific steps – not the documentation. Her goal is to allow scientists to see digital and data as a superpower, reducing non-value adding activities, and driving us towards a world where we can use in-silico experimentation and data in combination with in vitro experimentation to accelerate innovative medicines to patients.
Data & digitalization leader for JNJ small molecule analytical development labs. I define and deliver on a digital transformation strategy for the labs. I coach and support functional scientist to successfully complete projects which contribute to the long term goals of the teams and the department in the fields of data capture, data analytics and data modelling.
iCMC Digital Transformation program is a global top program aiming at digitizing all R&D labs within Sanofi, covering 10+ countries and 2500+ users overall. The value it is bringing to our company is huge and goes from data integrity to faster time to clinics and time-to-market. It is based on a data-centered end to end approach, covering data capture from lab equipment and workflows automation, data governance, data integration, and data consumer.
Dr. Nandini Kumar is a foremost expert on developing and executing digital transformation strategies. With over 20 years of experience spanning biopharma, academia, and the technology sector, she specializes in transitioning to connected, data-centric lab environments. In her role, Dr. Nandini works on all aspects of lab digitization – from evaluating new systems and tools to redesigning processes and scientific workflows to implementing new data infrastructure. She has enabled numerous R&D labs through technology road mapping, system deployments, integration of IoT/lab automation, and developing data governance models. One of Dr. Nandini’s key initiatives has been consolidating disparate data sources into ELN. This allows real-time capture, contextualizing data from instruments, sensors, assays, and manual entries.
Dennis is an informatician with 10+ years of experience within the pharmaceutical industry. With a strong background in software development and business analysis, Dennis started his journey in the global Digital Transformation program of CMC labs for Sanofi in 2021 and is now building and supporting to shape the future of digital laboratory work with a sustainable strategy.
Guillaume is a bio-informatician with +20 years of experience working with Research and Development data within Sanofi Digital R&D organization. Since 2021, Guillaume joined the global Digital Transformation program of CMC labs at Sanofi, across R&D and Manufacturing organizations, and take the responsibility of the global data capture platform delivered to more than 2500 scientists (covering all modalities). The scope of the platform is based on a data-centered end-to-end approach, covering data capture from lab equipment and workflows automation (ELN templates, digital recipe design, and automation platform) until data integration with Sanofi data foundation systems.
Dr. Nandini Kumar is a foremost expert on developing and executing digital transformation strategies. With over 20 years of experience spanning biopharma, academia, and the technology sector, she specializes in transitioning to connected, data-centric lab environments. In her role, Dr. Nandini works on all aspects of lab digitization – from evaluating new systems and tools to redesigning processes and scientific workflows to implementing new data infrastructure. She has enabled numerous R&D labs through technology road mapping, system deployments, integration of IoT/lab automation, and developing data governance models. One of Dr. Nandini’s key initiatives has been consolidating disparate data sources into ELN. This allows real-time capture, contextualizing data from instruments, sensors, assays, and manual entries.
Guillaume is a bio-informatician with +20 years of experience working with Research and Development data within Sanofi Digital R&D organization. Since 2021, Guillaume joined the global Digital Transformation program of CMC labs at Sanofi, across R&D and Manufacturing organizations, and take the responsibility of the global data capture platform delivered to more than 2500 scientists (covering all modalities). The scope of the platform is based on a data-centered end-to-end approach, covering data capture from lab equipment and workflows automation (ELN templates, digital recipe design, and automation platform) until data integration with Sanofi data foundation systems.
Dennis is an informatician with 10+ years of experience within the pharmaceutical industry. With a strong background in software development and business analysis, Dennis started his journey in the global Digital Transformation program of CMC labs for Sanofi in 2021 and is now building and supporting to shape the future of digital laboratory work with a sustainable strategy.
Data analysis and computational methods driving innovation within drug discovery
I am a seasoned IT architect with a Master’s degree in IT Management. In 2012, I began my career at Bayer, where I have been involved in the digitalization of research and development processes. For the past seven years, I have served as a Cloud Architect in R&D, and for the last four years, I have been dedicated to the development of the Clinical Data Intelligence Platform. I am deeply committed to leveraging technology to drive innovation and efficiency in the healthcare industry.
Live Lab sessions are interactive group discussions which tackle the bigger questions of the day in an open forum to brainstorm ideas and discuss the roadblocks to break-through innovation. They take the format of moderated standing discussions. The objective is to share views and experiences to stimulate new ways of thinking about common objectives.
Interdisciplinary research collaborations carry big potential for delivering breakthrough innovations urgently needed to tackle the world’s complex challenges impacting humanity: from overcoming a global health crisis to combating climate change.
To unlock the vast potential of innovation, it is essential to embrace scientific exchange and provide collaborative engagement projects, platforms, and communities.
Join this session to explore how Bayer leverages science collaborations and the collective innovation potential of its 16 000 R&D employees through various formats, e.g., via its Life Science Collaboration Program (LSC) and discuss how we can collectively enhance the efficacy of partnerships to shape a better future.
We will discuss approaches and learnings on these topics through the lenses of business leaders, scientific users, IT delivery and data management stewards across different scientifically driven market verticals such as Pharma, C>, Food and fast-moving consumer goods (FMCG
Paul Denny-Gouldson is a dynamic and accomplished professional in the field of digital science & scientific informatics. With a strong background in science, software and data management, he excels in leveraging cutting-edge technologies to solve complex scientific problems. Throughout his career, Paul has demonstrated expertise in developing innovative scientific informatics solutions that streamline scientific workflows, enhance data management, and drive data-driven decision-making. His exceptional proficiency in simple communication of complex topics, coupled with his extensive knowledge of science, applications, data integration and analysis, has enabled him to successfully lead interdisciplinary teams and deliver impactful results. Paul’s passion for scientific discovery, coupled with his keen problem-solving abilities, make him a valuable asset in any scientific informatics endeavour.
AstraZeneca’s High Throughput Screening facility recently made a significant move from Alderley Park, Cheshire to The Discovery Centre in Cambridge. This relocation involved the installation of four new automation platforms directly into The Discovery Centre, as well as the transfer of five automation platforms from Cheshire to Cambridge.
Here we will delve into the challenges encountered during the initial installation phase and explore how the insights gained were leveraged for the subsequent relocation and installation. These efforts were crucial in ensuring the seamless continuation of scientific activities, minimizing any impact on project delivery and ensuring the platforms were ready for planned scientific activities.
Maintenance and optimization for lab equipment, and sustainability initiatives in lab operations
Tamara graduated with a BSc (Hons) in Chemistry, from the University of Witwatersrand. After graduating, she spent some time working as a process metallurgist for a Mining Research and Technology business before moving into the LIMS industry. She has behind her more than 22+ years’ experience in the laboratory information technology and services industry, where she held positions in Services, Sales & Strategic Accounts Management. Tamara joined Clinisys in May 2023 and is now the Director, Global LIMS Sales.
Nicole Moberg is a Chief Executive Officer in Life Sciences with Genesis Reference Laboratories (GRL). GRL is a laboratory dedicated to providing superior lab testing with an excellent customer experience, to support better patient outcomes.
A native of Prince Edward Island, Canada, Nicole graduated from the University of Central Florida (UCF) with a Master in Change Management and joined the UCF faculty team where she taught business for over 10 years. Nicole was a consultant for the Disney Entrepreneur Center where she advised businesses on their leadership and strategy practices; was part of a team that launched UCF’s first academic Professional Selling Program; and partnered with companies to launch the university’s first Professional MBA Program. Moberg also consulted companies on building sales teams and enhancing client relationships through training and process improvement.
Nicole has a demonstrated history in various leadership roles in healthcare, most recently as CEO at Genesis, as Chief Operating Officer with Thrive Senior Living, and prior to that, Chief Sales Officer in biotech where she led a team through a restructure, several expansions, and was instrumental in new product launches. Nicole has completed an executive program in leadership from Harvard Business School Executive Education and received formal board training through University of Washington.
AI-based real-time analysis of cell fates – CellVoyant has developed AI-technology using live cell imaging to accurately monitor and analyse cell behavior in real time, improving insights into stem cell development to aid cell therapy development.
Enhancing differentiation protocols with AI – We are combining AI with advanced experimental design to fine-tune the experimental protocols for differentiation stem cells, aiming for better quality and reproducibility.
Toward an automated, AI-driven stem cell lab – Our roadmap includes developing a fully automated lab that uses AI to continuously improve and optimise differentation protocols, aiming to streamline operations and enhance research outcomes.
Molecular glues are a fascinating new type of drug with the potential to drastically improve medicine development for many diseases
– However to date these have largely only been discovered by luck
– How we developed a biology-led screening engine to learn the rules for molecular glue development and open up new routes for small molecule design
The novel AI toolkit presented in this work is a pioneering endeavor to connect the dots from drug development to treatment selection within the realm of cancer care.
At the foundation of our approach lies the utilization of causal models in the target discovery phase, which are validated using CRISPR screening on various cancer models to confirm the relevance of identified targets for therapeutic intervention.
I’m a bioinformatics scientist and the head of Bioinformatics and Omics Data Science Platform at the Berlin Institute of Medical Systems Biology, Max Delbrück Center in Berlin. I have been developing computational methods for analyzing and integrating large-scale genomics data sets since 2002. I mainly use machine learning and statistics to uncover patterns related to important biological variables such as disease state and type. I spent some time in the USA, Norway, Turkey, Japan, and Switzerland in order to pursue research work and education related to statistics, machine learning and bioinformatics.
The underlying aim of my current work is utilizing complex molecular signatures to provide decision support systems for disease diagnostics and biomarker discovery. In addition to the research efforts and managing a scientific lab, since 2015, I have been organizing and teaching at computational genomics courses in Berlin with participants from across the world.
Historically data generated during pharmaceutical development has been stored in data siloes separated by business processes, batches and disconnected systems. In order to accelerate pharmaceutical development and to meet future regulatory requirements, there is a need to structure and connect relevant data on drug substance and product. The presentation will outline our future vision and first steps to connect lab data in knowledge graphs.
